CoChat
Sign Up
Cited by 77Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and TreatmentsDrug Transport and Resistance Mechanisms

Characterisation of patients with a complete biochemical response to ursodeoxycholic acid.

Open access
Jorgensen, R A, Dickson, E R, Hofmann, A F, Rossi, S S, Lindor, K D·1995·Gut
DOI 10.1136/gut.36.6.935PMC PMC1382637
Open this paper in CoChat — free accountOpen PDF

Abstract

Ursodeoxycholic acid (UDCA) leads to biochemical and clinical improvement in many patients with primary biliary cirrhosis (PBC); although, the response is variable. This study compared UDCA treated patients with complete normalisation of biochemical functions to those without such improvement. Of the 65 patients receiving UDCA, 12 (19%) showed normalisation of liver biochemical functions at two years. The remaining 53 patients showed a less complete response. Mean (SD) alkaline phosphatase and total serum bilirubin values were significantly lower at entry in the patients whose liver biochemistry tests normalised (912 (732) U/l v 1417 (1021) U/l, p = 0.003, and 0.7 (12.1 (5.2) mumol/l v 38.9 (48.5) mumol/l, p = 0.0002, respectively), and percentage of UDCA in biliary bile acid was higher (56.3 (9.5)% v 38.3 (21.1)%, p = 0.03). Patients with biochemically and histologically less severe disease, and greater enrichment of biliary bile with UDCA, are more likely to respond favourably to the drug. The main objective of continued study will be to find out if normal liver biochemical functions can retard disease progression. The association of greater UDCA enrichment with complete biochemical responses suggests that higher doses of UDCA should be evaluated.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gut.36.6.935

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • About 20% of PBC patients will have normalization of liver biochemistries after 2 years.

    “About 20% of patients will have normalization of liver biochemistries after 2 years. (148)”

    From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [148]

    The Results report that 12 of 65 patients with PBC receiving ursodeoxycholic acid (19%) had normalized liver biochemical values after two years. This supports the approximate percentage and timing, but the claim omits the treatment condition and reads as applying to PBC patients generally. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 22

  1. Kaplan MM. Primary biliary cirrhosis. N EnglJ Med 1987; 316: 521-8.
  2. Poupon RE, Balkau B, Eschwege E, Poupon R. A multi- center, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991; 324: 1548-54.
  3. Van Berge Henegouwen GP, Brandt KH, Eyssen H, Parmentier G. Sulfated and unsulfated bile acids in serum, bile, and urine of patients with cholestasis. Gut 1976; 17: 861-9.
  4. Stiehl A, Rudolph G, Raedsch R, Moller B, Hopf U, Lotterer E, et al. Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis. Hepatology 1990; 12: 492-7.
  5. Galle PR, Theilmann L, Raedsch R, Otto G, Stiehl A. Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. Hepatology 1990; 12: 486-91.
  6. Yoshikawa M, Tsujii T, Matsumura K, Yamao J, Matsumura Y, Kubo R, et al. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 1992; 16: 358-64.
  7. Leuschner U, Fischer H, Kurtz W, Guldutuna S, Hubner K, Hellstern A, et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989; 97: 1268-74.
  8. Batta AK, Arora R, Salen G, Katz S. Ursodeoxycholic acid improves liver function and reduces serum and urinary endogenous bile acids in primary biliary cirrhosis. Hepatology 1988; 8: 1221.
  9. Hadziyannis S, Hadziyannis E. A randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis (PBC) [Abstract]. Hepatology 1988; 8: 1421.
  10. Ludwig J, Dickson ER, McDonald GSA. Staging of chronic nonsuppurative cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A 1978; 379: 103-12.
  11. Rossi SS, Converse JL, Hofmann AF. High pressure liquid chromatographic analysis of conjugated bile acids in human bile: simultaneous resolution of sulfated and unsulfated lithocholyl amidates and the common con- jugated bile acids. Jf Lipid Res 1987; 28: 589-95.
  12. Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, et ad. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106: 1284-90.
  13. Lillienau J, Schteingart CD, Hofman AF. Physiochemical and physiological properties of cholylsarcosine: a potential replacement detergent for bile acid deficiency states in the small intestine. Jf Clin Invest 1992; 89: 420-31.
  14. Heuman DM, Vlahcevic ZR, Pandak WM, Hylemon PB, Kim YS, Lillienau J, et al. Effect of cholylsarcosine on hepatic cholesterol and bile acid synthesis and bile secre- tion in rats. Gastroenterology 1992; 103: 1641-8.
  15. Wolfhagen FHJ, van Buuren HR, van Berge Henegouwen GP, van Hattum J, Eskens F, Kerbert-Dreteler MJ, et al. Can ursodeoxycholic acid monotherapy induce disease remission in primary biliary cirrhosis? Hepatology 1993; 18: 220A.
  16. Dickson ER, Fleming TR, Wiesner RH, Baldus WP, Fleming CR, Ludwig J, et al. Trial of penicillamine in advanced primary biliary cirrhosis. N Engl Jf Med 1985; 312: 1011-5.
  17. Neuberger J, Christensen E, Portmann B, Caballeria J, Rodes J, Ranek L, et al. Double blind controlled trial of D-penicillamine in patients with primary biliary cirrhosis. Gut 1985; 26: 114-9.
  18. Matloff DS, Alpert E, Resnick RH, Kaplan MM. A prospective trial of D-penicillamine in primary biliary cirrhosis. N Engl tJMed 1982; 306: 319-26.
  19. Bodenheimer HC Jr, Schaffner F, Pezullo J. Evaluation of colchicine therapy in primary biliary cirrhosis. Gastroenterology 1988; 96: 124-9.
  20. Kaplan MM, Alling DW, Zimmerman HJ, Wolfe HJ, Sepersky RA, Hirsch GS, et al. A prospective trial of colchicine for primary biliary cirrhosis. N Engl Jf Med 1986; 315: 1448-54.
  21. Hoofnagle JH, Davis GL, Schafer DF, Peters M, Avigan MI, Pappas SC, et al. Randomized trial of chlorambucil for primary biliary cirrhosis. Gastroenterology 1986; 91: 1327-34.
  22. Wiesner RH, Ludwig J, Lindor KD, Jorgensen RA, Baldus WP, Homburger HA, et al. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. NEnglJMed 1990; 322: 1419-24. on July 27, 2023 by guest. Protected by copyright. http://gut.bmj.com/ Gut: first published as 10.1136/gut.36.6.935 on 1 June 1995. Downloaded from

Cited by

Sorted by citations

Authors
Jorgensen, R. A., Dickson, E. R., Hofmann, A. F., Rossi, S. S., & Lindor, K. D.
Affiliations
Mayo Clinic (US)
ORCID
Lindor, K D
Venue
Gut
Publisher
BMJ
Published
1995-06
Volume
36
Issue
6
Pages
935-938
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
DOI
10.1136/gut.36.6.935
PMC
PMC1382637
OpenAlex
W2113962724
Cited by
77
References
1
Citations by year
2026: 2 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 1 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 1 · 2016: 1 · 2015: 2 · 2014: 3 · 2013: 2 · 2012: 3
FWCI
4.27
Type
journal article
Language
en
Open access
Locations
  • Gut (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
ursodeoxycholic acid, primary biliary cirrhosis, biochemical response, treatment response prediction, alkaline phosphatase, serum bilirubin, biliary bile acids, disease severity, disease progression
MeSH terms
Adult, Aged, Alkaline Phosphatase, Bile, Bilirubin, Double-Blind Method, Female, Follow-Up Studies, Humans, Immunoglobulin M, Liver, Liver Cirrhosis, Biliary, Male, Middle Aged, Ursodeoxycholic Acid, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review